TAIPEI, Taiwan, Nov. 3, 2015 /PRNewswire/ -- Medeon Biodesign, Inc. (TWSE: 6499), a Taiwan medical device company, is pleased to announce that the Company has successfully completed first-in-man studies for its XProTM suture-mediated vascular closure device, targeting to close 8F-21F femoral access sites.
XProTM suture-mediated vascular closure devices were successfully deployed in ten consecutive patients undergoing interventional catheterization procedures using 14F-18F sheaths. The devices achieved immediate or rapid hemostasis at the puncture sites with excellent clinical outcome including fast ambulation and discharge from hospital demonstrating the safety and effectiveness of percutaneous large bore closure using XProTM suture-mediated vascular closure devices.
"Interventional procedures that involve large bore access usually require major dissection of tissues, cut down of blood vessels and surgical repair of the access sites, whereas a percutaneous approach is less traumatic for patients and can achieve faster recovery," said Dr. Adrian Ebner, a world renown interventional cardiologist and Director of Catheterization Laboratory, Sanatorio Italiano Hospital in Asuncion, Paraguay, "A large bore vascular closure device for percutaneous procedures needs to be safe, rapid closing and easy to use. We have conducted first-in-man clinical studies using XProTM suture-mediated vascular closure device and are very pleased with its outstanding performance. I believe this device can be useful in large bore procedures such as TAVI (Transcatheter Aortic Valve Implantation) and EVAR (Endovascular Aneurysm Repair)."
Dr. Chao-Yung Wang, an interventional cardiologists at Linkou Chang Gung Memorial Hospital in Taiwan who has used this device in earlier pre-clinical studies and reviewed the first-in-man data commented "I am very pleased to see XProTM's ease of use and very short hemostasis time in this clinical setting, and believe that patients who undergo large bore interventional procedures can benefit from an innovative device like this.".
"Besides TAVI and EVAR, other interventional procedures that require large bore access also include Thoracic Endovascular Aortic Repair (TEVAR), Transcatheter Mitral Valve Repair (TMVR), Percutaneous Balloon Valvuloplasty (PBV), and Percutaneous Ventricular Assist Device (pVAD). XProTM addresses the need of a rapidly growing market." says Dr. Yue-Teh Jang, CEO of Medeon Biodesign. "Currently, there are very limited device options indicated for large bore access sites and many improvement opportunities for currently marketed devices. We believe that the XProTM suture-mediated vascular closure device can provide a new choice for interventionalists and patients worldwide.
About Medeon Biodesign
Medeon Biodesign is a publicly traded company located in Taipei, Taiwan, and currently listed on the Emerging Stock Board of the Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.
Dr. Yi-Ju Chen
SOURCE Medeon Biodesign, Inc.